HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
25 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
MFN2
mitofusin 2
Chromosome 1 Β· 1p36.22
NCBI Gene: 9927Ensembl: ENSG00000116688.19HGNC: HGNC:16877UniProt: O95140
324PubMed Papers
24Diseases
0Drugs
198Pathogenic Variants
FUNCTIONAL ROLE
Hub Gene
RESEARCH IMPACT
TrendingVariant-Rich
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
protein bindingprotein localization to phagophore assembly sitemitochondrionubiquitin protein ligase bindingCharcot-Marie-Tooth disease type 2A2Charcot-Marie-Tooth disease, axonal, autosomal recessive, type 2a2b;neuropathy, hereditary motor and sensory, type 6AAutosomal dominant Charcot-Marie-Tooth disease type 2A2
✦AI Summary

MFN2 is a mitochondrial outer membrane GTPase that mediates mitochondrial fusion and clustering through formation of homotypic and heterotypic protein complexes 1. Beyond fusion, MFN2 has evolved critical regulatory roles in cellular homeostasis. It tethers the endoplasmic reticulum to mitochondria, facilitating calcium signaling and inter-organelle communication 2. MFN2 binds phosphatidylserine and promotes ER-to-mitochondrial phospholipid transfer, essential for mitochondrial membrane synthesis and metabolic function 3. MFN2 coordinates glycolysis with oxidative phosphorylation through interaction with PKM2, a key regulatory axis in cancer metabolism 4. The protein is required for efficient mitophagy via PRKN recruitment and quality control of dysfunctional mitochondria 5. MFN2 dysfunction causes hereditary neuropathies including Charcot-Marie-Tooth disease type 2A 5. MFN2 deficiency triggers non-alcoholic fatty liver disease (NASH) through disrupted ER-mitochondrial phospholipid homeostasis and ER stress 3. Enhanced MFN2-mediated mitochondria-ER contact improves CD8+ T cell metabolic fitness and anti-tumor immunity 6. Collectively, MFN2 integrates mitochondrial dynamics with metabolic signaling, calcium homeostasis, and cellular quality control.

Sources cited
1
MFN2 mediates mitochondrial fusion through homotypic and heterotypic complexes and is essential for embryonic development
PMID: 12527753
2
MFN2 tethers ER to mitochondria and is required for efficient mitochondrial calcium uptake
PMID: 19052620
3
MFN2 binds phosphatidylserine and promotes PS transfer to mitochondria; MFN2 deficiency causes NASH through disrupted ER-mitochondrial phospholipid homeostasis
PMID: 31051106
4
MFN2 interacts with PKM2 to promote mitochondrial fusion and OXPHOS while attenuating glycolysis
PMID: 30887444
5
MFN2 mutations are linked to neurodegenerative diseases including Charcot-Marie-Tooth disease type 2A and influence bioenergetics and mitophagy
PMID: 40149969
6
MFN2 enhances mitochondria-ER contact through SERCA2 interaction, supporting CD8+ T cell metabolic fitness and anti-tumor immunity
PMID: 37738362
Disease Associationsβ“˜24
Charcot-Marie-Tooth disease type 2A2Open Targets
0.82Strong
Charcot-Marie-Tooth disease, axonal, autosomal recessive, type 2a2b;Open Targets
0.81Strong
neuropathy, hereditary motor and sensory, type 6AOpen Targets
0.81Strong
Autosomal dominant Charcot-Marie-Tooth disease type 2A2Open Targets
0.80Strong
multiple symmetric lipomatosisOpen Targets
0.65Moderate
hereditary motor and sensory neuropathy type 6Open Targets
0.63Moderate
Charcot-Marie-Tooth disease type 2Open Targets
0.57Moderate
Charcot-Marie-Tooth diseaseOpen Targets
0.54Moderate
genetic disorderOpen Targets
0.54Moderate
severe early-onset axonal neuropathy due to MFN2 deficiencyOpen Targets
0.45Moderate
hereditary motor and sensory neuropathyOpen Targets
0.42Moderate
axonal neuropathyOpen Targets
0.41Moderate
Distal muscle weaknessOpen Targets
0.41Moderate
Charcot-Marie-Tooth disease type 5Open Targets
0.37Weak
Tip-toe gaitOpen Targets
0.36Weak
microcephalyOpen Targets
0.34Weak
Abnormal blistering of the skinOpen Targets
0.34Weak
Decreased body weightOpen Targets
0.34Weak
EMG abnormalityOpen Targets
0.34Weak
hyperpigmentation of the skinOpen Targets
0.34Weak
Charcot-Marie-Tooth disease, axonal, type 2A2AUniProt
Charcot-Marie-Tooth disease, axonal, type 2A2BUniProt
Lipomatosis, multiple symmetric, with or without peripheral neuropathyUniProt
Neuropathy, hereditary motor and sensory, 6A, with optic atrophyUniProt
Pathogenic Variants198
NM_014874.4(MFN2):c.2119C>T (p.Arg707Trp)Pathogenic
Charcot-Marie-Tooth disease, axonal, autosomal recessive, type 2a2b;|not provided|Charcot-Marie-Tooth disease type 2A2|Charcot-Marie-Tooth disease type 2|Inborn genetic diseases|Charcot-Marie-Tooth disease|MFN2-related disorder|Charcot-Marie-Tooth disease type 2A2;Charcot-Marie-Tooth disease, axonal, autosomal recessive, type 2a2b;|Hereditary motor and sensory neuropathy with optic atrophy;Charcot-Marie-Tooth disease, type 2A|Multiple symmetric lipomatosis|Peripheral axonal neuropathy|Charcot-Marie-Tooth disease type 2A2;Neuropathy, hereditary motor and sensory, type 6A;Charcot-Marie-Tooth disease, axonal, autosomal recessive, type 2a2b;|Neuropathy, hereditary motor and sensory, type 6A|Tip-toe gait|Semidominant MFN2-related disorders
β˜…β˜…β˜†β˜†2026β†’ Residue 707
NM_014874.4(MFN2):c.227T>C (p.Leu76Pro)Pathogenic
Charcot-Marie-Tooth disease type 2A2|not provided|Charcot-Marie-Tooth disease type 2|Inborn genetic diseases
β˜…β˜…β˜†β˜†2026β†’ Residue 76
NM_014874.4(MFN2):c.2219G>C (p.Trp740Ser)Pathogenic
Charcot-Marie-Tooth disease type 2A2|Charcot-Marie-Tooth disease type 2|not provided|Hereditary motor and sensory neuropathy with optic atrophy;Charcot-Marie-Tooth disease type 2A2;Charcot-Marie-Tooth disease, axonal, autosomal recessive, type 2a2b;|not specified|Charcot-Marie-Tooth disease|Inborn genetic diseases|MFN2-related disorder
β˜…β˜…β˜†β˜†2026β†’ Residue 740
NM_014874.4(MFN2):c.382C>T (p.His128Tyr)Pathogenic
not provided|Charcot-Marie-Tooth disease type 2|Charcot-Marie-Tooth disease type 2A2
β˜…β˜…β˜†β˜†2026β†’ Residue 128
NM_014874.4(MFN2):c.326A>G (p.Lys109Arg)Pathogenic
Charcot-Marie-Tooth disease type 2|Charcot-Marie-Tooth disease type 2A2
β˜…β˜…β˜†β˜†2026β†’ Residue 109
NM_014874.4(MFN2):c.839G>A (p.Arg280His)Pathogenic
Charcot-Marie-Tooth disease type 2A2|not provided|Charcot-Marie-Tooth disease type 2|Charcot-Marie-Tooth disease|Neuropathy, hereditary motor and sensory, type 6A|Charcot-Marie-Tooth disease type 2A2;Neuropathy, hereditary motor and sensory, type 6A;Charcot-Marie-Tooth disease, axonal, autosomal recessive, type 2a2b;|Charcot-Marie-Tooth disease, axonal, autosomal recessive, type 2a2b;
β˜…β˜…β˜†β˜†2026β†’ Residue 280
NM_014874.4(MFN2):c.314C>T (p.Thr105Met)Pathogenic
not provided|Charcot-Marie-Tooth disease type 2|Cerebellar ataxia|Charcot-Marie-Tooth disease type 2A2|Neuropathy, hereditary motor and sensory, type 6A
β˜…β˜…β˜†β˜†2026β†’ Residue 105
NM_014874.4(MFN2):c.775C>T (p.Arg259Cys)Pathogenic
Charcot-Marie-Tooth disease type 2A2|not provided|Charcot-Marie-Tooth disease type 2|Charcot-Marie-Tooth disease|Inborn genetic diseases
β˜…β˜…β˜†β˜†2025β†’ Residue 259
NM_014874.4(MFN2):c.1085C>T (p.Thr362Met)Pathogenic
Charcot-Marie-Tooth disease type 2A2|Charcot-Marie-Tooth disease, axonal, autosomal recessive, type 2a2b;|Charcot-Marie-Tooth disease|Hereditary motor and sensory neuropathy with optic atrophy|Charcot-Marie-Tooth disease type 2|not provided|Inborn genetic diseases|Charcot-Marie-Tooth disease type 2A2;Neuropathy, hereditary motor and sensory, type 6A|MFN2-related disorder
β˜…β˜…β˜†β˜†2025β†’ Residue 362
NM_014874.4(MFN2):c.838C>T (p.Arg280Cys)Likely pathogenic
not provided|Multiple system atrophy, cerebellar type|Charcot-Marie-Tooth disease type 2
β˜…β˜…β˜†β˜†2025β†’ Residue 280
NM_014874.4(MFN2):c.1090C>T (p.Arg364Trp)Pathogenic
Hereditary motor and sensory neuropathy with optic atrophy|Charcot-Marie-Tooth disease type 2A2|Charcot-Marie-Tooth disease type 2|not provided|Charcot-Marie-Tooth disease|Charcot-Marie-Tooth disease type 4
β˜…β˜…β˜†β˜†2025β†’ Residue 364
NM_014874.4(MFN2):c.310C>T (p.Arg104Trp)Pathogenic
Hereditary motor and sensory neuropathy with optic atrophy|Charcot-Marie-Tooth disease type 2A2|Charcot-Marie-Tooth disease|not provided|Charcot-Marie-Tooth disease type 2|Hereditary motor and sensory neuropathy with optic atrophy;Charcot-Marie-Tooth disease type 2A2;Charcot-Marie-Tooth disease, axonal, autosomal recessive, type 2a2b;|Inborn genetic diseases|Charcot-Marie-Tooth disease, axonal, autosomal recessive, type 2a2b;|Neuropathy, hereditary motor and sensory, type 6A|Charcot-Marie-Tooth disease dominant intermediate B
β˜…β˜…β˜†β˜†2025β†’ Residue 104
NM_014874.4(MFN2):c.711A>T (p.Glu237Asp)Pathogenic
not provided|Charcot-Marie-Tooth disease type 2
β˜…β˜…β˜†β˜†2025β†’ Residue 237
NM_014874.4(MFN2):c.281G>A (p.Arg94Gln)Pathogenic
Charcot-Marie-Tooth disease type 2A2|not provided|Charcot-Marie-Tooth disease type 2|Charcot-Marie-Tooth disease|Neuropathy, hereditary motor and sensory, type 6A|Charcot-Marie-Tooth disease, axonal, autosomal recessive, type 2a2b;|Inborn genetic diseases
β˜…β˜…β˜†β˜†2025β†’ Residue 94
NM_014874.4(MFN2):c.1126A>G (p.Met376Val)Pathogenic
Charcot-Marie-Tooth disease type 2|not provided|Hereditary motor and sensory neuropathy with optic atrophy|Charcot-Marie-Tooth disease type 2A2|Inborn genetic diseases|MFN2-related disorder|Hereditary neuropathy or pain disorder
β˜…β˜…β˜†β˜†2025β†’ Residue 376
NM_014874.4(MFN2):c.617C>T (p.Thr206Ile)Pathogenic
Hereditary motor and sensory neuropathy with optic atrophy|Charcot-Marie-Tooth disease|not provided|Charcot-Marie-Tooth disease type 2
β˜…β˜…β˜†β˜†2025β†’ Residue 206
NM_014874.4(MFN2):c.436C>T (p.Leu146Phe)Pathogenic
Charcot-Marie-Tooth disease type 2A2|not provided|Charcot-Marie-Tooth disease type 2
β˜…β˜…β˜†β˜†2025β†’ Residue 146
NM_014874.4(MFN2):c.497C>T (p.Ala166Val)Pathogenic
Charcot-Marie-Tooth disease type 2|Charcot-Marie-Tooth disease type 2A2|Inborn genetic diseases
β˜…β˜…β˜†β˜†2025β†’ Residue 166
NM_014874.4(MFN2):c.1160+1G>ALikely pathogenic
Charcot-Marie-Tooth disease type 2|Charcot-Marie-Tooth disease, axonal, autosomal recessive, type 2a2b;
β˜…β˜…β˜†β˜†2025
NM_014874.4(MFN2):c.280C>G (p.Arg94Gly)Pathogenic
Charcot-Marie-Tooth disease|Charcot-Marie-Tooth disease type 2|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 94
View on ClinVar β†—
Related Genes
DNM1LProtein interaction100%TRAK1Protein interaction100%ITPR1Protein interaction100%TRAK2Protein interaction99%MFFProtein interaction99%DNM1Protein interaction99%
Tissue Expression6 tissues
Heart
100%
Liver
17%
Brain
17%
Lung
13%
Bone Marrow
13%
Ovary
9%
Gene Interaction Network
Click a node to explore
MFN2DNM1LTRAK1ITPR1TRAK2MFFDNM1
PROTEIN STRUCTURE
Preparing viewer…
PDB6JFK Β· 2.00 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.60LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.47 [0.36–0.60]
RankingsWhere MFN2 stands among ~20K protein-coding genes
  • #1,018of 20,598
    Most Researched324 Β· top 5%
  • #340of 5,498
    Most Pathogenic Variants198 Β· top 10%
  • #4,134of 17,882
    Most Constrained (LOEUF)0.60 Β· top quartile
Genes detectedMFN2
Sources retrieved25 papers
Response timeβ€”
πŸ“„ Sources
25β–Ό
1
Deficient Endoplasmic Reticulum-Mitochondrial Phosphatidylserine Transfer Causes Liver Disease.
PMID: 31051106
Cell Β· 2019
1.00
2
Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development.
PMID: 12527753
J Cell Biol Β· 2003
0.90
3
The Balance of MFN2 and OPA1 in Mitochondrial Dynamics, Cellular Homeostasis, and Disease.
PMID: 40149969
Biomolecules Β· 2025
0.80
4
PKM2 coordinates glycolysis with mitochondrial fusion and oxidative phosphorylation.
PMID: 30887444
Protein Cell Β· 2019
0.70
5
MFN2 suppresses clear cell renal cell carcinoma progression by modulating mitochondria-dependent dephosphorylation of EGFR.
PMID: 37378422
Cancer Commun (Lond) Β· 2023
0.64